Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa

Next Previous
X
Search
Trial Profile

An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilobelimab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors InflaRx

    • Most Recent Events

    • 18 Jan 2020 Results published in the British Journal of Dermatology
    • 23 May 2019 According to an InflaRx media release, retrospective long-term from this completed trial has been presented at the 8th Conference of the European Hidradenitis Suppurativa Foundation.
    • 28 Aug 2018 According to an InflaRx media release, the company will host an R&D Day on Hidradenitis Suppurativa and its scientific and clinical experience with its breakthrough anti-C5a monoclonal antibody IFX-1, on Friday, September 7 in New York City. they will provide an update on the current IFX-1 clinical phase II development in HS, and speak to other C5a mediated disease opportunities.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top